Pharaoh Neuro

About Pharaoh Neuro

Pharaoh Neuro is a medical device company developing therapeutic solutions for complex neurological conditions. The company is focused on improving outcomes in neurocritical care by addressing secondary injuries that complicate patient recovery.

The company's portfolio includes two primary products. The first is the Neurapheresis™ Cerebrospinal Fluid (CSF) Management System, an active, closed-loop system designed to remove blood and neurotoxins from the CSF. This clinical-stage platform aims to treat patients with subarachnoid hemorrhage and has potential applications for other conditions such as ALS, multiple sclerosis, and meningitis. The system is designed to accelerate the return to normal CSF composition, thereby reducing inflammation and long-term complications compared to the standard of care like passive drains. The Neurapheresis™ system is currently for investigational use and has not been cleared by the FDA for sale in the United States.

The second product is the MindsEye™ Expandable Port, a neurosurgical access device. It consists of a translucent, durable sheath that creates an adjustable working channel for surgeons. This design provides an unobstructed view for reaching lesions deep within the brain, supports various optical tools like endoscopes and microscopes, and is compatible with bimanual instruments. The goal of the MindsEye port is to enhance visibility, maximize surgical exposure, and provide flexibility during neurosurgical procedures.

The company's strategy is to provide tools that help neurosurgeons and neurocritical care teams manage risks and prevent secondary injuries, allowing them to focus on the primary condition with greater confidence. Pharaoh Neuro is backed by investors including Arboretum Ventures and its CEO is Rich Nazarian.